Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems
In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and r...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/6/1412 |
| _version_ | 1827715530335715328 |
|---|---|
| author | Maria Grazia Ferraro Marialuisa Piccolo Gabriella Misso Francesco Maione Daniela Montesarchio Michele Caraglia Luigi Paduano Rita Santamaria Carlo Irace |
| author_facet | Maria Grazia Ferraro Marialuisa Piccolo Gabriella Misso Francesco Maione Daniela Montesarchio Michele Caraglia Luigi Paduano Rita Santamaria Carlo Irace |
| author_sort | Maria Grazia Ferraro |
| collection | DOAJ |
| description | In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex—named AziRu—incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting of breast cancer cells (BBC). Mechanisms of action have been widely explored in the context of preclinical evaluations in vitro, highlighting a multitarget action on cell death pathways which are typically deregulated in neoplasms onset and progression. Moreover, being AziRu inspired by the well-known NAMI-A complex, information on non-nanostructured Ru-based anticancer agents have been included in a precise manner. |
| first_indexed | 2024-03-10T19:21:15Z |
| format | Article |
| id | doaj.art-cd756fc1b53648b589fb65baac3db765 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T19:21:15Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-cd756fc1b53648b589fb65baac3db7652023-11-20T03:00:25ZengMDPI AGCells2073-44092020-06-0196141210.3390/cells9061412Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid NanosystemsMaria Grazia Ferraro0Marialuisa Piccolo1Gabriella Misso2Francesco Maione3Daniela Montesarchio4Michele Caraglia5Luigi Paduano6Rita Santamaria7Carlo Irace8Department of Pharmacy, School of Medicine and Surgery, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, ItalyDepartment of Pharmacy, School of Medicine and Surgery, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, ItalyDepartment of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, ItalyDepartment of Pharmacy, School of Medicine and Surgery, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, ItalyDepartment of Chemical Sciences, University of Naples “Federico II”, Via Cintia 421, 80126 Naples, ItalyDepartment of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, ItalyDepartment of Chemical Sciences, University of Naples “Federico II”, Via Cintia 421, 80126 Naples, ItalyDepartment of Pharmacy, School of Medicine and Surgery, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, ItalyDepartment of Pharmacy, School of Medicine and Surgery, University of Naples “Federico II”, Via D. Montesano 49, 80131 Naples, ItalyIn this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex—named AziRu—incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting of breast cancer cells (BBC). Mechanisms of action have been widely explored in the context of preclinical evaluations in vitro, highlighting a multitarget action on cell death pathways which are typically deregulated in neoplasms onset and progression. Moreover, being AziRu inspired by the well-known NAMI-A complex, information on non-nanostructured Ru-based anticancer agents have been included in a precise manner.https://www.mdpi.com/2073-4409/9/6/1412breast cancer (BC) therapyruthenium complexesruthenium-based nanosystemspreclinical studiescell death pathwaysmultitarget drugs |
| spellingShingle | Maria Grazia Ferraro Marialuisa Piccolo Gabriella Misso Francesco Maione Daniela Montesarchio Michele Caraglia Luigi Paduano Rita Santamaria Carlo Irace Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems Cells breast cancer (BC) therapy ruthenium complexes ruthenium-based nanosystems preclinical studies cell death pathways multitarget drugs |
| title | Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems |
| title_full | Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems |
| title_fullStr | Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems |
| title_full_unstemmed | Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems |
| title_short | Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems |
| title_sort | breast cancer chemotherapeutic options a general overview on the preclinical validation of a multi target ruthenium iii complex lodged in nucleolipid nanosystems |
| topic | breast cancer (BC) therapy ruthenium complexes ruthenium-based nanosystems preclinical studies cell death pathways multitarget drugs |
| url | https://www.mdpi.com/2073-4409/9/6/1412 |
| work_keys_str_mv | AT mariagraziaferraro breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT marialuisapiccolo breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT gabriellamisso breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT francescomaione breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT danielamontesarchio breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT michelecaraglia breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT luigipaduano breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT ritasantamaria breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems AT carloirace breastcancerchemotherapeuticoptionsageneraloverviewonthepreclinicalvalidationofamultitargetrutheniumiiicomplexlodgedinnucleolipidnanosystems |